Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249385 | 0.98 | KMT2A (0.66) | KMT2AALDH1A1KDM4ECYP3A4MAPT | |
| SCHEMBL5616342 | 0.89 | KMT2A (0.56) | KMT2AALDH1A1KDM4ECYP3A4MAPT | |
| N-Benzylmethylamine SCHEMBL28452678 | 0.86 | KDM4E (0.65) | KMT2AALDH1A1KDM4ECYP3A4MAPT | |
| SCHEMBL5499807 | 0.83 | KMT2A (0.50) | KMT2AALDH1A1NR1H4EPHX2SRD5A2 | |
| Hydrochloric Acid SCHEMBL15392980 | 0.83 | ALDH1A1 (0.78) | KMT2AALDH1A1KDM4ENR1H4EPHX2 | |
| SCHEMBL11864213 | 0.82 | ALDH1A1 (0.62) | KMT2AALDH1A1KDM4EMAPTNR1H4 | |
| SCHEMBL24178010 | 0.81 | ALDH1A1 (0.59) | KMT2AALDH1A1KDM4ENR1H4EPHX2 | |
| SCHEMBL10131958 | 0.81 | KMT2A (0.68) | KMT2AALDH1A1KDM4ECYP3A4MAPT | |
| SCHEMBL3503996 | 0.80 | ALDH1A1 (0.81) | KMT2AALDH1A1KDM4ENR1H4EPHX2 | |
| Hydrochloric Acid SCHEMBL9638765 | 0.80 | LOXL2 (0.61) | KMT2AMAPTHPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306647-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-09-29 | — | — | US | disclosed |
| US-20220227785-A1 | NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-07-21 | — | — | US | disclosed |
| EP-3962914-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962912-A1 | NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2022-03-09 | — | — | EP | disclosed |
| CN-113767101-A | Novel indole-2-carboxamides having anti-Hepatitis B Virus (HBV) activity | 艾库里斯有限及两合公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-113767102-A | Novel phenyl and pyridylureas having activity against Hepatitis B Virus (HBV) | 艾库里斯有限及两合公司 | 2021-12-07 | — | — | CN | disclosed |
| WO-2020221826-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020221816-A1 | NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-05 | — | — | WO | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-4990533-A | Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity | WARNER-LAMBERT CO. (US) | 1991-02-05 | — | — | US | disclosed |
| US-4980095-A | Sodium salt of N-C4-carboxybenzyl nonanamide | WARNER-LAMBERT COMPANY (US) | 1990-12-25 | — | — | US | disclosed |
| US-4771064-A | Benzoic acid and benzoic acid ester derivatives having antiflammatory and analgesic activity | WARNER-LAMBERT COMPANY (US) | 1988-09-13 | — | — | US | disclosed |
| US-4755518-A | Imidazolyl or tetrazolyl substituted benzoic acid derivatives and pharmaceutical compositions thereof | WARNER-LAMBERT COMPANY (US) | 1988-07-05 | — | — | US | disclosed |
| US-4719232-A | Benzoic acid and benzoic acid ester derivatives to treat headaches | WARNER-LAMBERT COMPANY (US) | 1988-01-12 | — | — | US | disclosed |
| US-4719234-A | Benzoic acid and benzoic acid ester derivatives to treat inflammation | WARNER-LAMBERT COMPANY (US) | 1988-01-12 | — | — | US | disclosed |
| US-4719233-A | Benzoic acid and benzoic acid ester derivatives to treat pain | WARNER-LAMBERT COMPANY (US) | 1988-01-12 | — | — | US | disclosed |
| US-4689182-A | Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity | WARNER-LAMBERT COMPANY (US) | 1987-08-25 | — | — | US | disclosed |
| CN-86108626-A | Phenylformic acid and benzoate derivatives with anti-inflammatory and pain palliation efficacy | — | 1987-07-22 | — | — | CN | disclosed |
| EP-0226223-A2 | Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity | WARNER-LAMBERT COMPANY (US) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227785-A1 | NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDKN1A, CDK2 | KMT2A 2823/4885ALDH1A1 4309/4885KDM4E 707/4885 |
| US-20220306647-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | HCCS, IDO1, BRD4 | KMT2A 1228/4885ALDH1A1 3923/4885KDM4E 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.